© 2005 European Society for Medical Oncology
Original article |
Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
Department of Medical Oncology, Airedale General Hospital, Skipton Road, Steeton, Keighley BD20 6TD, UK
* Correspondence to: Dr S. M. Crawford, Department of Medical Oncology, Airedale General Hospital, Skipton Road, Steeton, Keighley BD20 6TD, UK. Tel: +44-1535-292947; Fax: +44-1535-292948; Email: michael.crawford{at}anhst.nhs.uk
The tumour marker CA125 is an important indicator of the clinical progress of women with carcinoma of the ovary. We have investigated the interval from the nadir CA125 value to progression defined by rising CA125 (time to biochemical progression, TBP), and overall survival of patients treated with chemotherapy for this disease in relation to the nadir CA125 value in patients in whom this was <30 U/ml following chemotherapy. The median TBP in group A (38 patients, nadir 
10 U/ml) was 2436 days, in group B (32 patients, nadir 11–20) 182 days and in group C (nine patients, nadir 21–30) 90 days, (P < 0.001). This was associated with similar differences for overall survival, the median was 2968 days in group A, 537 days in group B and 537 days in group C, (P < 0.001). Variations in the CA125 value even within the normal range carry useful information. This prognostic indicator will be useful in studying the management of patients following response to first-line chemotherapy.
Key words: CA125, carcinoma of the ovary, prognosis, response to chemotherapy, tumour markers
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Prat, M. Parera, B. Adamo, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, J. Baselga, and J. M. del Campo Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann. Onc., February 1, 2009; 20(2): 294 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Handy The Clinical Utility of Tumor Markers Lab Med, February 1, 2009; 40(2): 99 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prat, M. Parera, and J. M. Del Campo Prognostic Role of CA-125 Nadir in Stage IV Epithelial Ovarian Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1771 - 1772. [Full Text] [PDF]
|
|
|
|
|
|
A. Prat, M. Parera, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, I. Roxana, J. Baselga, and J. M. Del Campo Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer Ann. Onc., February 1, 2008; 19(2): 327 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jackson, R. A. Craven, R. C. Hutson, I. Graze, P. Lueth, R. P. Tonge, J. L. Hartley, J. A. Nickson, S. J. Rayner, C. Johnston, et al. Proteomic Profiling Identifies Afamin as a Potential Biomarker for Ovarian Cancer Clin. Cancer Res., December 15, 2007; 13(24): 7370 - 7379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Coleman, A. Gordon, J. Barter, S. Sun, W. Rackoff, and T. J. Herzog Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients Oncologist, January 1, 2007; 12(1): 72 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Riedinger, J. Wafflart, G. Ricolleau, N. Eche, H. Larbre, J. P. Basuyau, I. Dalifard, K. Hacene, and M. F. Pichon CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study Ann. Onc., August 1, 2006; 17(8): 1234 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Markman Normal CA-125 and the Risk of Progression in Ovarian Cancer J. Clin. Oncol., July 10, 2006; 24(20): 3310 - 3310. [Full Text] [PDF]
|
|
|
|
|
|
M. Markman, P.Y. Liu, M. L. Rothenberg, B. J. Monk, M. Brady, and D. S. Alberts Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian Cancer J. Clin. Oncol., March 20, 2006; 24(9): 1454 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sabbatini and D. R. Spriggs Consolidation for Ovarian Cancer in Remission J. Clin. Oncol., February 1, 2006; 24(4): 537 - 539. [Full Text] [PDF]
|
|
|
|
|
|
R. Agarwal and S. B Kaye Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann. Onc., January 1, 2005; 16(1): 4 - 6. [Full Text] [PDF]
|
|